DPP-4

Sigaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S4002 Sitagliptin phosphate monohydrate 41 mg/mL 100 mg/mL <1 mg/mL
S3031 Linagliptin <1 mg/mL 17 mg/mL 1 mg/mL
S3033 Vildagliptin (LAF-237) 60 mg/mL 60 mg/mL 60 mg/mL
S1540 Saxagliptin 63 mg/mL 63 mg/mL 24 mg/mL
S2868 Alogliptin(SYK-322)benzoate 2 mg/mL 68 mg/mL <1 mg/mL
S8565 Omarigliptin (MK-3102) <1 mg/mL 79 mg/mL <1 mg/mL
S4697 Saxagliptin hydrate 1 mg/mL 66 mg/mL 66 mg/mL
S4636 Teneligliptin hydrobromide 100 mg/mL 100 mg/mL 17 mg/mL
S7513 Trelagliptin <1 mg/mL 71 mg/mL 3 mg/mL
Catalog No. Information Product Use Citations Product Validations
S4002

Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.

S3031

Linagliptin

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9.

S3033

Vildagliptin (LAF-237)

Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM.

S1540

Saxagliptin

Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.

S2868

Alogliptin(SYK-322)benzoate

Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

S8565New

Omarigliptin (MK-3102)

Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).

S4697New

Saxagliptin hydrate

Saxagliptin H2O is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.

S4636New

Teneligliptin hydrobromide

Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.

S7513

Trelagliptin

Trelagliptin is a highly selective, long-acting DPP-4 inhibitor. Phase 3.

Catalog No. Information Product Use Citations Product Validations
S4002

Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.

S3031

Linagliptin

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9.

S3033

Vildagliptin (LAF-237)

Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM.

S1540

Saxagliptin

Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.

S2868

Alogliptin(SYK-322)benzoate

Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

S8565New

Omarigliptin (MK-3102)

Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).

S4697New

Saxagliptin hydrate

Saxagliptin H2O is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.

S4636New

Teneligliptin hydrobromide

Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.

S7513

Trelagliptin

Trelagliptin is a highly selective, long-acting DPP-4 inhibitor. Phase 3.

Tags: DPP-4 inhibition | DPP-4 inhibitor diabetes | DPP-4 enzyme | DPP-4 inhibitors mechanism | DPP-4 drugs | DPP-4 cancer | DPP-4 inhibitors list | DPP-4 activity | DPP-4 inhibitors drugs | DPP-4 inhibitors review | new DPP-4 inhibitor | DPP-4 assay | DPP-4 inhibitors cancer | FDA approved DPP-4 inhibitors